Compare Delta Air Lines, Inc. (DAL) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Gilead Sciences, Inc. — how do they compare? Delta Air Lines, Inc. trades at $79.19 (market cap $54.02B), while Gilead Sciences, Inc. trades at $147 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 3.4× Delta Air Lines, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Gilead Sciences, Inc. for 111 Days on average.
| DAL | GILD | |
|---|---|---|
Market Cap | $54.02B | $182.40B |
Volume | 9,632,845 | 4,469,821 |
Sector | Industrials | Health |
52-Week High | $93.66 | $155.80 |
52-Week Low | $55.65 | $116.74 |
Typical Hold Time | 97 Days | 111 Days |
Enterprise Value | $69.34B | $205.46B |
Dividend Yield | 1.05% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.97, down 0.82% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $63.36 billion in 2025, while profitability metrics remain solid with a 5.78% net income margin and 20.12% ROE. Analyst sentiment remains overwhelmingly positive with 82% buy ratings and a $103.36 consensus price target representing 25% upside potential.
DAL presents a compelling investment case with attractive valuation multiples (P/E of 13.76, P/S of 0.8) and strong cash flow generation, though near-term headwinds include fuel cost volatility and competitive pressures. The stock's technical weakness contrasts with fundamental strength, creating potential opportunity for patient investors. Key risks include oil price sensitivity and execution challenges in maintaining premium customer loyalty against aggressive competitor tactics.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
